REGENERON PHARMACEUTICALS, INC. Funds and ETFs Regeneron Pharmaceuticals, Inc.
Equities
REGN
US75886F1075
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 982.3 USD | +1.48% |
|
+0.87% | +11.84% |
ETFs positioned on Regeneron Pharmaceuticals, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 1 M€ | +3.03% | - | |
| 0.08% | 306 M€ | +6.54% | - | |
| 0.08% | 39 M€ | +6.43% | - | |
| 0.08% | 756 M€ | +0.82% | - | |
| 0.08% | 2 M€ | +3.16% | - | |
| 0.06% | 12 M€ | +14.24% | - | |
| 0.06% | 104 M€ | +10.57% | ||
| 0.05% | 105 M€ | +4.23% | - | |
| 0.05% | 6 M€ | +3.89% | ||
| 0.04% | 17 M€ | +3.40% | - | |
| 0.03% | 54 M€ | +1.07% | - | |
| 0.02% | 8 M€ | +1.17% | - | |
| 0.02% | 234 M€ | +5.72% | - | |
| 0.02% | 6 M€ | -4.26% | - | |
| 0.01% | 169 M€ | +0.93% | - | |
| 0.02% | 34 M€ | +3.87% | - | |
| 7.27% | 129 M€ | +8.31% | - | |
| 8.38% | 28 M€ | +8.16% | - |
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
982.3
USD
Average target price
1,042
USD
Spread / Average Target
+6.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.84% | 106B | |
| +9.42% | 115B | |
| -2.74% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B | |
| -24.95% | 8.23B |
- Stock Market
- Equities
- REGN Stock
- Funds and ETFs Regeneron Pharmaceuticals, Inc.
